Personalis, Inc. (NASDAQ:PSNL) CEO John Stephen West Sells 110,000 Shares

Personalis, Inc. (NASDAQ:PSNL) CEO John Stephen West sold 110,000 shares of the stock in a transaction that occurred on Tuesday, June 8th. The shares were sold at an average price of $22.43, for a total transaction of $2,467,300.00. Following the completion of the sale, the chief executive officer now directly owns 670,520 shares of the company’s stock, valued at approximately $15,039,763.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of PSNL stock opened at $23.30 on Friday. Personalis, Inc. has a 52 week low of $11.05 and a 52 week high of $53.46. The stock has a market cap of $1.02 billion, a PE ratio of -19.58 and a beta of 1.49. The firm has a 50 day simple moving average of $22.28.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, May 5th. The company reported ($0.29) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.08. Personalis had a negative net margin of 55.43% and a negative return on equity of 21.21%. Analysts forecast that Personalis, Inc. will post -1.62 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. NEXT Financial Group Inc acquired a new stake in shares of Personalis in the 4th quarter valued at $25,000. AdvisorNet Financial Inc acquired a new stake in shares of Personalis in the 4th quarter valued at $27,000. Penserra Capital Management LLC raised its holdings in shares of Personalis by 171.2% in the 4th quarter. Penserra Capital Management LLC now owns 895 shares of the company’s stock valued at $32,000 after purchasing an additional 565 shares in the last quarter. Banque Cantonale Vaudoise acquired a new stake in shares of Personalis in the 4th quarter valued at $33,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Personalis during the 4th quarter worth $47,000. Institutional investors and hedge funds own 67.53% of the company’s stock.

A number of equities analysts recently weighed in on PSNL shares. Truist lowered their price objective on shares of Personalis from $37.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, May 13th. Oppenheimer raised shares of Personalis from a “market perform” rating to an “outperform” rating and set a $28.00 price objective for the company in a research report on Thursday, May 6th. Morgan Stanley lowered their price objective on shares of Personalis from $38.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, May 7th. Finally, Needham & Company LLC lowered their price objective on shares of Personalis from $38.00 to $33.00 and set a “buy” rating for the company in a research report on Thursday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. Personalis has an average rating of “Buy” and a consensus price target of $35.50.

Personalis Company Profile

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

See Also: Compound Interest and Why It Matters When Investing

Insider Buying and Selling by Quarter for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.